Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Karyopharm Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -153.3%. For fiscal 2025 it was -134.2%, against -52.6% the year before. The highest annual figure on record is -52.6% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -134.2% | −81.6 |
| FY2024 | Dec 31, 2024 | -52.6% | +45.4 |
| FY2023 | Dec 31, 2023 | -98.0% | +7.2 |
| FY2022 | Dec 31, 2022 | -105.2% | −46.1 |
| FY2021 | Dec 31, 2021 | -59.1% | +122.5 |
| FY2020 | Dec 31, 2020 | -181.6% | +306.5 |
| FY2019 | Dec 31, 2019 | -488.1% | +100.0 |
| FY2018 | Dec 31, 2018 | -588.1% | +7448.3 |
| FY2017 | Dec 31, 2017 | -8036.4% | +63117.5 |
| FY2016 | Dec 31, 2016 | -71153.9% | −23881.5 |
| FY2015 | Dec 31, 2015 | -47272.4% | −14182.0 |
| FY2014 | Dec 31, 2014 | -33090.4% | −24318.6 |
| FY2013 | Dec 31, 2013 | -8771.8% | −6265.8 |
| FY2012 | Dec 31, 2012 | -2506.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -200.5% | −102.3 |
| Q1 FY2026 | Mar 31, 2026 | -63.9% | +14.3 |
| Q4 FY2025 | Dec 31, 2025 | -299.9% | −199.1 |
| Q3 FY2025 | Sep 30, 2025 | -75.2% | +7.5 |
| Q2 FY2025 | Jun 30, 2025 | -98.2% | −153.8 |
| Q1 FY2025 | Mar 31, 2025 | -78.2% | +34.6 |
| Q4 FY2024 | Dec 31, 2024 | -100.8% | +23.2 |
| Q3 FY2024 | Sep 30, 2024 | -82.7% | +13.1 |
| Q2 FY2024 | Jun 30, 2024 | 55.6% | +142.4 |
| Q1 FY2024 | Mar 31, 2024 | -112.8% | −24.6 |
| Q4 FY2023 | Dec 31, 2023 | -124.0% | −9.3 |
| Q3 FY2023 | Sep 30, 2023 | -95.8% | +4.7 |
| Q2 FY2023 | Jun 30, 2023 | -86.8% | +36.8 |
| Q1 FY2023 | Mar 31, 2023 | -88.2% | −1.3 |
| Q4 FY2022 | Dec 31, 2022 | -114.7% | −145.3 |
| Q3 FY2022 | Sep 30, 2022 | -100.5% | +37.0 |
| Q2 FY2022 | Jun 30, 2022 | -123.6% | +113.4 |
| Q1 FY2022 | Mar 31, 2022 | -86.8% | +160.0 |
| Q4 FY2021 | Dec 31, 2021 | 30.7% | +154.4 |
| Q3 FY2021 | Sep 30, 2021 | -137.5% | +113.3 |
| Q2 FY2021 | Jun 30, 2021 | -237.1% | −98.6 |
| Q1 FY2021 | Mar 31, 2021 | -246.8% | +45.0 |
| Q4 FY2020 | Dec 31, 2020 | -123.7% | +145.1 |
| Q3 FY2020 | Sep 30, 2020 | -250.8% | +63.8 |
| Q2 FY2020 | Jun 30, 2020 | -138.5% | +318.8 |
| Q1 FY2020 | Mar 31, 2020 | -291.8% | +42392.7 |
| Q4 FY2019 | Dec 31, 2019 | -268.8% | +27988.5 |
| Q3 FY2019 | Sep 30, 2019 | -314.6% | +19803.8 |
| Q2 FY2019 | Jun 30, 2019 | -457.3% | −288.1 |
| Q1 FY2019 | Mar 31, 2019 | -42684.5% | −42299.9 |
| Q4 FY2018 | Dec 31, 2018 | -28257.3% | −25712.3 |
| Q3 FY2018 | Sep 30, 2018 | -20118.4% | +959448.3 |
| Q2 FY2018 | Jun 30, 2018 | -169.2% | +43826.4 |
| Q1 FY2018 | Mar 31, 2018 | -384.6% | +56923.9 |
| Q4 FY2017 | Dec 31, 2017 | -2545.0% | +50423.8 |
| Q2 FY2017 | Jun 30, 2017 | -979566.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -43995.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -57308.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -52968.8% | – |
See a number that looks wrong?